BMS-833923

BMS-833923 is an orally bioavailable small molecule inhibitor of Smoothened receptor (SMO), a key component of the Hedgehog (Hh) signaling pathway. By antagonizing SMO, BMS‑833923 suppresses Hh pathway activity, which plays a critical role in cellular growth, differentiation, and repair. Aberrant activation of this pathway is implicated in various cancers and tumorigenesis. The drug was originally discovered by Exelixis and later developed by Bristol Myers Squibb for potential antineoplastic applications. It has demonstrated preclinical efficacy in reducing cell proliferation and inducing apoptosis in cancer cell lines such as esophageal adenocarcinoma, medulloblastoma, pancreatic carcinoma, multiple myeloma, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML). Clinical development reached phase II for several indications but was discontinued for chronic myeloid leukemia[1][3][4][5][6][7].

Other names

N-(2-Methyl-5-((methylamino)methyl)phenyl)-4-((4-phenylquinazolin-2-yl)amino)benzamide